Table 2.
Genotype | Constant | Cortex | Striatum | Hippocampus | Cerebellum |
---|---|---|---|---|---|
WT (n = 8) | Kd, nM | 1.2 ± 0.42 | 1.1 ± 0.17 | 1.3 ± 0.16 | 0.9 ± 0.18 |
Bmax, pmol/mg protein | 0.37 ± 0.04 | 0.40 ± 0.08 | 0.38 ± 0.04 | 0.34 ± 0.04 | |
Tg174 (n = 6) | Kd, nM | 1.4 ± 0.16 | 0.76 ± 0.14 | 0.69 ± 0.12 | 0.65 ± 0.11 |
Bmax, pmol/mg protein | 5.3 ± 0.71*† | 2.2 ± 0.36* | 1.8 ± 0.22* | 0.78 ± 0.08 | |
Tg166 (n = 6) | Kd, nM | 1.6 ± 0.36 | 1.1 ± 0.44 | 1.1 ± 0.48 | 0.60 ± 0.09 |
Bmax, pmol/mg protein | 2.1 ± 0.36* | 1.4 ± 0.17 | 1.5 ± 0.58 | 0.52 ± 0.14 |
[3H]Glibenclamide binding to cell membranes from brain regions dissected from WT and Tg mice was assessed by using saturation assays. Values represent the mean ± SEM. The striata and hippocampi from two mice were pooled for each assay.
, Significantly different from WT mice, P < 0.05, ANOVA followed by Tukey's multiple comparison test.
†, Significantly different from Tg166 mice, P < 0.05, ANOVA followed by Tukey's test.